Group items tagged

Market Overview: Next-generation antibody therapeutics includes the use of new improvised therapeutic antibody to form innovative medicines for treating various diseases. Next-generation antibody therapeutics is developed clinically by pharmaceutical and biotechnology companies for several diseases. The Next Generation Antibody Therapeutics Market size was worth $ XX million in 2018 and is forecasted to reach $ XX million by 2026, expected to grow at a high CAGR during the forecast period 2019-2026. Market Dynamics: The Next Generation Antibody Therapeutics Market is growing due to several factors such as rising incidence of chronic diseases, increasing emergence of antibody technology, new drug discovery, large number of government initiatives, and growing research and development activities for new therapies. Rising prevalence of chronic disease such as cancer, asthma, diabetes and COPD are boosting the growth of the next generation antibody therapeutics market. For instance, according to National Cancer Institute in 2018, in United States, an estimated 1,735,350 new cases of cancer will be diagnosed and 609,640 people will die from the disease. The development of next-generation monoclonal antibodies has expanded beyond oncology into all therapeutic areas. For instance, ADCs were initially focused primarily on cancer, but Genentech has applied to infectious diseases, leading to the discovery and development of THIOMAB antibiotic conjugates (TACs) for the treatment of methicillin-resistant Staphylococcus aureus (MRSA). The technological advancements in antibody therapeutics have led to the development of more efficient antibody therapeutics, hence, driving the growth in the next-generation antibody therapeutics market. However, stringent government regulation, high cost and time required for research and development activities are some of the factors hindering the growth for global next-generation antibody therapeutics market. Market Segmentation: Based o

This market was valued at $4.4 billion in 2011 and is expected to reach $5.8 billion by 2016, at a CAGR of 5.3% from 2011 to 2016.

The Global Diabetic Foot Ulcer Market was valued at $4.48 billion in 2018 and is anticipated to exhibit 11.34% CAGR from 2019 to 2026, reaching $ XX billion by 2026.

This report studies the global nuclear medicine market over the forecast period 2012-2017. The global radiopharmaceutical market was valued at $3.8 billion in 2012 and is poised to reach $5.5 billion by 2017 at a CAGR of 7.8%.

This report studies the global nuclear medicine market over the forecast period 2012-2017. The global radiopharmaceutical market was valued at $3.8 billion in 2012 and is poised to reach $5.5 billion by 2017 at a CAGR of 7.8%.

The global MR systems market was valued at $4 billion and $4.1 billion in 2011 and 2012, respectively. As of March 2013, the market is expected to be $4.13 billion and is poised to reach approximately $5.24 billion by 2018 at a CAGR of 4.56%.

The global digital X-ray market is estimated to be worth $4.82 billion by 2018, growing at a CAGR of 4.5% from 2013 to 2018.

The Asia-Pacific radiopharmaceutical market was valued at $500.8 million in 2012 and is poised to reach $824.9 million by 2017 at a CAGR of 10.5%.

The North America home healthcare market was valued at $90.9 billion in 2012; it is poised to grow at a CAGR of 7.5% to reach $130.4 billion by 2017.

[475 Pages Report] Interventional Cardiology Devices Market was valued at $8.7 billion in 2011 and is poised to grow at a CAGR of 7.8% to reach $12.7 billion by 2016.

The Global Bioinformatics Market was valued at $2.9 billion in 2012 and is poised to reach $7.5 billion by 2017 at a CAGR of 20.9%. Bioinformatics Technologies are used in various pharmaceutical and biotechnology sectors to support their growth.

The global digital X-ray market is estimated to be worth $4.82 billion by 2018, growing at a CAGR of 4.5% from 2013 to 2018. The digital X-ray market is divided into three segments based on types, major products and applications in imaging. Based on types, the market is segmented into computed radiography and digital radiography; the latter is the fastest-growing market.

Chromatography reagents market is expected to grow at healthy CAGR. Inventive methods, increasing demands and investment inflows will drive the global industry.

Animal vaccines market is growing at steady CAGR. Increasing incidences of diseases and investments from different sectors will drive the market further.

The global vital signs monitoring market was valued at $3,148 million in the year 2012 and is poised to grow at a CAGR of 6.61% from the year 2013, reaching approximately $4,375 million by 2018.

Nerve repair market will grow at steady CAGR. Increasing aging population, chronic diseases and awareness will be the key drivers for the global industry.

The patient monitoring devices market was worth $14.2 billion in the year 2011 and is expected to grow at a CAGR of 5.9% from 2011 to 2016 to reach $18.9 billion.

Global medical electronics market report on the medical electronics market analyzes the medical electronics supply chain, giving a very clear insight of all major and supported segments to the industry. According to report the total value of medical electronics market is expected to reach $56.50 Billion by 2020, growing at a CAGR of 5.5% from 2014 to 2020.

The global catheter stabilization device market is expected to reach $1,372.35 Million by 2020 from $957.26 Million in 2015, growing at a CAGR of 7.47% between 2015 and 2020. Securement devices are used to secure catheters and infusion or drainage devices and to facilitate their operations. They can be repositioned upon initial application unlike normal dressing tapes, and are water-resistant devices made of latex-free, soft-cloth materials and are water resistant. The scope of the catheter stabilization device market includes securement devices used in surgeries and home healthcare settings.

On the basis of regions, the market is divided into North America, Europe, Asia, and the Rest of the World (RoW). The Rest of the World region comprises Latin America, Pacific countries, and Middle East and Africa. In 2014, North America accounted for the largest share of the antibody production market, followed by Europe and Asia. However, the Asian market is slated to grow at the highest CAGR in the coming five years and serves as a revenue pocket for the companies offering antibody productions.